Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy

Abstract

The results of these experiments indicate that BLI monitoring can be used as a surrogate for predicting survival benefit from TMZ treatment, permits early determination of relative survival benefit associated with distinct TMZ therapeutic regimens, and offers a means of investigating secondary/salvage therapy efficacy following tumor regrowth from initial therapy.